A Study of LY3971297 in Healthy Participants

← catalyst calendar

NCT06148272 · readout ≤ 12 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

225estimated

Sites

Countries

Japan, Singapore, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-12-07

actual

When the study began enrolling

Primary completion

Aug 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2026

estimated

The whole study's end, after follow-up

First posted

2023-11-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Healthy
Obesity
Hypertension

Interventions

Drug: LY3971297
Drug: Placebo
Drug: LY3971297 IV

Primary outcomes

what the primary-completion date above is the date OF

Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

measured Baseline (Day of Exposure) to Day 29 post-dose

Part B, C, D, E, & G: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

measured Baseline (Day of Exposure) to Day 57 post-dose

Part F: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297

measured Baseline Up to Day 29 post-dose for Part F

Part F: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297

measured Baseline Up to Day 29 post-dose for Part F

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed